Movatterモバイル変換


[0]ホーム

URL:


ES2193726T3 - Formulaciones de aerosol medicinales. - Google Patents

Formulaciones de aerosol medicinales.

Info

Publication number
ES2193726T3
ES2193726T3ES99932599TES99932599TES2193726T3ES 2193726 T3ES2193726 T3ES 2193726T3ES 99932599 TES99932599 TES 99932599TES 99932599 TES99932599 TES 99932599TES 2193726 T3ES2193726 T3ES 2193726T3
Authority
ES
Spain
Prior art keywords
medicinal aerosol
active ingredient
aerosol formulations
microns
chromoglycinic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99932599T
Other languages
English (en)
Inventor
Manfred Keller
Kurt Herzog
Rudi Muller-Walz
Holger Kraus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jago Research AG
Original Assignee
Jago Research AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jago Research AGfiledCriticalJago Research AG
Application grantedgrantedCritical
Publication of ES2193726T3publicationCriticalpatent/ES2193726T3/es
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

Formulación aerosol medicinal, que abarca una sal sólida farmacéuticamente tolerable de ácido cromoglicínico y/o nedocromil en cantidad terapéutica y profilácticamente ineficaz en el intervalo de 5 a 250 micra g por impulsión de pulverización, una cantidad eficaz de un principio activo farmacéutico diferente a aquel, finamente dividido, con un diámetro medio de tamaño de partículas inferior a 6 micra m, y un agente propulsor líquido, no tóxico, en el cual el principio activo se presenta en forma suspendida.
ES99932599T1998-08-041999-08-02Formulaciones de aerosol medicinales.Expired - LifetimeES2193726T3 (es)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CH1633981998-08-04

Publications (1)

Publication NumberPublication Date
ES2193726T3true ES2193726T3 (es)2003-11-01

Family

ID=4215022

Family Applications (1)

Application NumberTitlePriority DateFiling Date
ES99932599TExpired - LifetimeES2193726T3 (es)1998-08-041999-08-02Formulaciones de aerosol medicinales.

Country Status (19)

CountryLink
US (1)US6475467B1 (es)
EP (1)EP1102579B1 (es)
JP (1)JP4672143B2 (es)
CN (1)CN1150890C (es)
AT (1)ATE234604T1 (es)
AU (1)AU749697B2 (es)
BE (1)BE2013C027I2 (es)
CA (1)CA2338680C (es)
CY (1)CY2012033I1 (es)
DE (1)DE59904648D1 (es)
DK (1)DK1102579T3 (es)
ES (1)ES2193726T3 (es)
FR (1)FR13C0057I2 (es)
LU (1)LU92254I2 (es)
NO (2)NO328096B1 (es)
NZ (1)NZ509489A (es)
PT (1)PT1102579E (es)
WO (1)WO2000007567A1 (es)
ZA (1)ZA200100569B (es)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AUPN814496A0 (en)*1996-02-191996-03-14Monash UniversityDermal penetration enhancer
GB9616237D0 (en)1996-08-011996-09-11Norton Healthcare LtdAerosol formulations
US20010031244A1 (en)1997-06-132001-10-18Chiesi Farmaceutici S.P.A.Pharmaceutical aerosol composition
DZ2947A1 (fr)1998-11-252004-03-15Chiesi Farma SpaInhalateur à compteur de dose sous pression.
GB9902689D0 (en)1999-02-081999-03-31Novartis AgOrganic compounds
DE19921693A1 (de)*1999-05-122000-11-16Boehringer Ingelheim PharmaNeuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en)*1999-05-122010-08-05Boehringer Ingelheim Pharma KgMedicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en)1999-07-142007-05-08Almirall AgQuinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es)1999-07-142003-04-01Almirall Prodesfarma SaNuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1313553B1 (it)1999-07-232002-09-09Chiesi Farma SpaFormulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
AR026914A1 (es)*1999-12-112003-03-05Glaxo Group LtdDistribuidor de medicamento
US6651655B1 (en)*2000-01-182003-11-25Quadrant Technologies LimitedInhaled vaccines
IT1317846B1 (it)2000-02-222003-07-15Chiesi Farma SpaFormulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en)2000-04-072000-05-31Arakis LtdThe treatment of respiratory diseases
CA2411047C (en)2000-05-222009-08-04Chiesi Farmaceutici S.P.A.Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060257324A1 (en)*2000-05-222006-11-16Chiesi Farmaceutici S.P.A.Pharmaceutical solution formulations for pressurised metered dose inhalers
FR2812545B1 (fr)*2000-08-032003-03-28Air Liquide Sante IntAerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
US20040081627A1 (en)*2000-10-092004-04-29Jinks Phillip AMedicinal aerosol formulations
HRP20030276B1 (en)*2000-10-122006-02-28Boehringer Ingelheim Pharma Gmbh & Co. Kg.Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
US6908928B2 (en)2000-10-122005-06-21Bi Pharma Kg.Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US6620438B2 (en)*2001-03-082003-09-16Boehringer Ingelheim Pharma KgPharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US7776315B2 (en)*2000-10-312010-08-17Boehringer Ingelheim Pharma Gmbh & Co. KgPharmaceutical compositions based on anticholinergics and additional active ingredients
SK288031B6 (sk)*2000-10-312012-12-03Boehringer Ingelheim Pharma Gmbh & Co. KgPropellant-free liquid inhalation formulation
US20020137764A1 (en)2000-10-312002-09-26Karin DrechselInhalable formulation of a solution containing a tiotropium salt
US20100310477A1 (en)*2000-11-282010-12-09Boehringer Ingelheim Pharma Gmbh & Co. Kg.Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10111843A1 (de)*2001-03-132002-09-19Boehringer Ingelheim PharmaVerbindungen zur Behandlung von inflammatorischen Erkrankungen
CN100496608C (zh)*2001-03-302009-06-10洁垢技术有限公司药用气溶胶制剂
US20030055026A1 (en)2001-04-172003-03-20Dey L.P.Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en)2001-04-172003-12-23Dey, L.P.Bronchodilating compositions and methods
US20030013675A1 (en)*2001-05-252003-01-16Boehringer Ingelheim Pharma KgCombination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US6472563B1 (en)*2001-11-092002-10-29Sepracor Inc.Formoterol tartrate process and polymorph
US6858615B2 (en)2002-02-192005-02-22Parion Sciences, Inc.Phenyl guanidine sodium channel blockers
PL209212B1 (pl)*2002-03-012011-08-31Chiesi Farma SpaSuperdrobny preparat formoterolu
DE10212264A1 (de)2002-03-202003-10-02Boehringer Ingelheim PharmaKristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7244415B2 (en)*2002-03-282007-07-17Boehringer Ingelheim Pharma Gmbh & Co. KgHFA suspension formulations of an anhydrate
US7311894B2 (en)*2002-03-282007-12-25Boehringer Ingelheim Pharma Gmbh & Co. KgHFA suspension formulations containing an anticholinergic
DE10214264A1 (de)*2002-03-282003-10-16Boehringer Ingelheim PharmaHFA-Suspensionsformulierungen eines Anhydrats
DE10214263A1 (de)*2002-03-282003-10-16Boehringer Ingelheim PharmaHFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
GB0207899D0 (en)*2002-04-052002-05-153M Innovative Properties CoFormoterol and cielesonide aerosol formulations
GB0207906D0 (en)*2002-04-052002-05-153M Innovative Properties CoFormoterol and mometasone aerosol formulations
US20050181032A1 (en)*2002-06-252005-08-18Acrux Dds Pty Ltd.Metastable pharmaceutical compositions
EP2266533A3 (en)*2002-06-252011-12-14Acrux DDS Pty LtdTransdermal delivery rate control using amorphous pharmaceutical compositions
US20050186141A1 (en)*2002-06-252005-08-25Acrux Dds Pty Ltd.Transdermal aerosol compositions
KR101166955B1 (ko)*2002-12-102012-07-19선오비온 파마슈티컬스 인코포레이티드레발부테롤 염
DK1572217T3 (da)*2002-12-122008-12-15Nycomed GmbhKombinationsmedikament af R,R-formoterol og ciclesonid
US20050058606A1 (en)*2002-12-162005-03-17Boehringer Ingelheim Pharma Gmbh & Co. KgTiotropium containing HFC solution formulations
US20040152720A1 (en)*2002-12-202004-08-05Boehringer Ingelheim Pharma Gmbh & Co. KgPowdered medicaments containing a tiotropium salt and salmeterol xinafoate
CN1292748C (zh)*2003-03-052007-01-03南昌弘益科技有限公司噻托溴铵吸入粉雾剂及其制备工艺
PT1608336E (pt)*2003-03-202008-04-21Boehringer Ingelheim PharmaFormulação para aerossol doseador utilizando hidro-fluroalcanos como propulsores
CA2525943A1 (en)*2003-05-222004-12-02Altana Pharma AgSalmeterol and ciclesonide combination
GB0312148D0 (en)2003-05-282003-07-02Aventis Pharma LtdStabilized pharmaceutical products
JP2006527237A (ja)2003-06-132006-11-30アルタナ ファルマ アクチエンゲゼルシャフトホルモテロールと及びシクレソニドの組合せ物
GB0315889D0 (en)*2003-07-082003-08-13Aventis Pharma LtdStable pharmaceutical products
TWI359675B (en)2003-07-102012-03-11Dey L PBronchodilating β-agonist compositions
US20050026948A1 (en)*2003-07-292005-02-03Boehringer Ingelheim International GmbhMedicaments for inhalation comprising an anticholinergic and a betamimetic
US20070071689A1 (en)*2003-08-062007-03-29Galephar M/FAdvantageous combination for inhalation of nacystelyn and bronchodilators
US7745442B2 (en)2003-08-202010-06-29Parion Sciences, Inc.Methods of reducing risk of infection from pathogens
PL1670482T5 (pl)2003-09-162022-10-03Covis Pharma GmbhZastosowanie cyklezonidu w leczeniu chorób układu oddechowego
WO2005027875A1 (en)*2003-09-182005-03-31Ivax CorporationParticles
GB0323685D0 (en)*2003-10-092003-11-12Jagotec AgImprovements in or relating to organic compounds
GB0323684D0 (en)2003-10-092003-11-12Jagotec AgImprovements in or relating to organic compounds
AU2005210084B2 (en)*2004-02-062010-06-24Meda Pharma Gmbh & Co. KgCombination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
SI1713473T1 (sl)*2004-02-062013-06-28Meda Pharma Gmbh & Co. KgKombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
RU2438660C2 (ru)*2004-02-062012-01-10Меда Фарма Гмбх Унд Ко. КгКомбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
EP1595531A1 (en)2004-05-132005-11-16CHIESI FARMACEUTICI S.p.A.Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2005082413A2 (en)*2004-02-272005-09-09Altana Pharma AgCiclesonide and glycopyrronium combination
US20070134165A1 (en)*2004-04-202007-06-14Altana Pharma AgUse of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
BRPI0510119A (pt)*2004-04-232007-09-25Cydex Incformulação para dpi contendo sulfoaquil éter de ciclodextrina
AU2013201437B2 (en)*2004-04-232015-09-03Cydex Pharmaceuticals, IncDPI formulation containing sulfoalkyl ether cyclodextrin
US20050238632A1 (en)*2004-04-232005-10-27Alburty David SPropellant formulations
ITRM20040268A1 (it)*2004-05-312004-08-31Italchimici S P AFormulazione farmaceutica di una soluzione stabile di formoterolo per via inalatoria e suo precedimento di preparazione.
ES2257152B1 (es)*2004-05-312007-07-01Laboratorios Almirall S.A.Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
PL1809243T5 (pl)*2004-07-022022-12-27Boehringer Ingelheim International GmbhPreparaty aerozolowe w postaci zawiesin z tg 227 ea jako propelent aerozolowy
DE102005029390A1 (de)*2005-06-232007-01-04Beiersdorf AgWirkstoffkombinationen aus Glycopyrroniumbromid und Polyolen
ATE520390T1 (de)2004-12-272011-09-15Beiersdorf AgGlycopyrrolat in kosmetischen zubereitungen
JP3955868B2 (ja)*2004-12-272007-08-08株式会社キングジム書類等の綴じ具
GB0501956D0 (en)*2005-01-312005-03-09Arrow InternatNebulizer formulation
EP1863476B1 (en)*2005-03-162016-02-03MEDA Pharma GmbH & Co. KGThe combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US20060239935A1 (en)*2005-04-232006-10-26Boehringer Ingelheim International GmbhCompositions for inhalation
WO2006114379A1 (de)*2005-04-232006-11-02Boehringer Ingelheim International GmbhArzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
PT1881980E (pt)2005-05-022012-12-06Boehringer Ingelheim IntNovas formas cristalinas de brometo de tiotrópio
BRPI0611134A2 (pt)2005-06-032010-08-17Acrux Dds Pty Ltdmétodo e composição para liberação transdérmica de fármaco
US7629331B2 (en)2005-10-262009-12-08Cydex Pharmaceuticals, Inc.Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2012200449B2 (en)*2005-12-212013-07-25Meda Pharma Gmbh & Co KgCombination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
PT2098248E (pt)2005-12-212012-08-27Meda Pharma Gmbh & Co KgCombinação de anticolinérgicos, glucocorticóides e agonistas de beta 2 para o tratamento de doenças inflamatórias
DE102006017320A1 (de)*2006-04-112007-10-18Boehringer Ingelheim Pharma Gmbh & Co. KgAerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
ES2298049B1 (es)*2006-07-212009-10-20Laboratorios Almirall S.A.Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
MX2009006037A (es)*2006-12-072009-06-16Lilly Co EliUn articulo de manufactura para prasugrel.
DE102007002121B4 (de)*2007-01-102008-12-11Dräger, Karl-HeinzVerwendung eines Flüssiggasgemisches als nichtbrennbares Treibgas zum Feinstverteilen eines Reiz- oder Kampfstoffes
CA2608561A1 (en)*2007-10-292009-04-29Carl PaluszkiewiczMotorcycle wind deflector accessory support
EP2100599A1 (en)2008-03-132009-09-16Laboratorios Almirall, S.A.Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en)2008-03-132009-09-16Laboratorios Almirall, S.A.Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2435024B1 (en)*2009-05-292016-07-06Pearl Therapeutics, Inc.Compositions for respiratory delivery of active agents and associated methods and systems
US8815258B2 (en)2009-05-292014-08-26Pearl Therapeutics, Inc.Compositions, methods and systems for respiratory delivery of two or more active agents
TR200907237A2 (tr)*2009-09-232011-04-21B�Lg�� MahmutTiotropyum kuru toz kombinasyonu
GB0918149D0 (en)2009-10-162009-12-02Jagotec AgImproved medicinal aerosol formulation
TR200907914A2 (tr)*2009-10-202011-05-23B�Lg�� MahmutKortlkosteroid içeren kuru toz formunda farmasötik bileşim.
AR079451A1 (es)2009-12-182012-01-25Nycomed GmbhCompuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
UA106098C2 (uk)2009-12-232014-07-25К'Єзі Фармачеутічі С.П.А.Аерозольна композиція для хозл
WO2011076841A2 (en)*2009-12-232011-06-30Chiesi Farmaceutici S.P.A.Combination therapy for copd
SG181868A1 (en)*2009-12-232012-07-30Chiesi Farma SpaCombination therapy for copd
TR200909792A2 (tr)2009-12-252011-07-21B�Lg�� MahmutTiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
TR200909789A2 (tr)*2009-12-252011-07-21B�Lg�� MahmutTiotropyum, budesonid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
US8834931B2 (en)2009-12-252014-09-16Mahmut BilgicDry powder formulation containing tiotropium for inhalation
TR200909793A2 (tr)*2009-12-252011-07-21B�Lg�� MahmutTiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
TR200909790A2 (tr)*2009-12-252011-07-21Bi̇lgi̇ç MahmutTiotropyum, formoterol ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
TR200909791A2 (tr)*2009-12-252011-07-21B�Lg�� MahmutSalmeterol ve flutikazon içeren farmasötik bileşim@
EP2510928A1 (en)2011-04-152012-10-17Almirall, S.A.Aclidinium for use in improving the quality of sleep in respiratory patients
GB201108039D0 (en)2011-05-132011-06-29Mexichem Amanco Holding SaCompositions
EP2721036B1 (en)2011-06-152015-07-22Takeda GmbHNovel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds
WO2012171900A1 (en)2011-06-172012-12-20Nycomed GmbhNovel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
AR086745A1 (es)2011-06-272014-01-22Parion Sciences Inc3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201117619D0 (en)2011-10-122011-11-23Mexichem Amanco Holding SaCompositions
GB201117621D0 (en)2011-10-122011-11-23Mexichem Amanco Holding SaCompositions
AU2013363218B2 (en)2012-12-172018-03-15Parion Sciences, Inc.Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
RU2018138195A (ru)2012-12-172018-12-18Пэрион Сайенсиз, Инк.Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
WO2014113638A1 (en)*2013-01-172014-07-24Aer Devices, Inc.Multi-use albuterol maintenance therapy formulations and devices therefor
MX361286B (es)2013-03-152018-12-03Pearl Therapeutics IncMétodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
GB201306984D0 (en)2013-04-172013-05-29Mexichem Amanco Holding SaComposition
US9102633B2 (en)2013-12-132015-08-11Parion Sciences, Inc.Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
SG11201605311UA (en)2013-12-302016-07-28Chiesi Farma SpaStable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
PT3104854T (pt)2014-02-102020-06-26Respivant Sciences GmbhEstabilizadores de mastócitos para tratamento de doença pulmonar
JP2017510624A (ja)2014-02-102017-04-13パタラ ファーマ リミテッド ライアビリティ カンパニー肥満細胞安定剤による全身性障害の治療
US10238625B2 (en)2015-08-072019-03-26Respivant Sciences GmbhMethods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en)2015-08-072019-04-23Respivant Sciences GmbhMethods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CA3007050C (en)2015-12-042020-12-08Mexichem Fluor S.A. De C.V.Pharmaceutical composition comprising a formoterol compound
AU2017321495A1 (en)2016-08-312019-03-21Respivant Sciences GmbhCromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CN116270640A (zh)2016-09-192023-06-23墨西哥氟石股份公司药物组合物
CA3037107C (en)2016-09-192021-05-18Mexichem Fluor S.A. De C.V.Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
ES2892673T3 (es)2016-09-192022-02-04Mexichem Fluor Sa De CvComposición farmacéutica que comprende glicopirrolato
WO2018067341A1 (en)2016-10-072018-04-12Patara Pharma, LLCCromolyn compositions for treatment of pulmonary fibrosis
WO2018069210A1 (en)2016-10-102018-04-19Takeda GmbhTetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
EP3525773A1 (en)*2016-10-142019-08-21Glenmark Specialty S.A.Nebulizable compositions of tiotropium and formoterol
UA122811C2 (uk)*2018-08-102021-01-06Наталія Миколаївна ТихонівськаФармацевтична композиція
MX2022004781A (es)2019-12-022022-05-16Chiesi Farm SpaLata de acero inoxidable para inhaladores dosificadores presurizados.
CN112972384B (zh)*2019-12-022022-03-18长风药业股份有限公司一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
JP2023519199A (ja)*2020-03-252023-05-10インスメッド インコーポレイテッドトレプロスチニルプロドラッグの医薬製剤及びその使用方法
EP4531922A1 (en)*2022-05-272025-04-09Chiesi Farmaceutici S.p.A.A pharmaceutical formulation for pressurised metered dose inhaler
EP4531920A1 (en)*2022-05-272025-04-09Chiesi Farmaceutici S.p.A.A pharmaceutical formulation for pressurised metered dose inhaler
PE20251253A1 (es)*2022-05-272025-05-06Chiesi Farm SpaFormulacion farmaceutica para inhalador presurizado de dosis medidas

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
BE555319A (es)1956-03-211900-01-01
BE556587A (es)1957-01-311957-04-11
IL51314A (en)*1976-01-301980-03-31Fisons LtdDisodium cromoglycate of low moisture content and pharmaceutical compositions containing it
US4405598A (en)*1976-01-301983-09-20Fisons, LimitedComposition for treating asthma
NL7708731A (nl)1976-08-131978-02-15Montedison SpaWerkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
CA1075854A (en)1976-08-161980-04-22Charles W. SimonsAerosol propellants for personal products
FR2390951A1 (fr)1977-05-171978-12-15OrealNouvelles compositions cosmetiques sous forme de laques aerosols pour fixer la chevelure
GB2077100B (en)*1980-04-301985-04-24Fisons LtdPharmaceutical compositions containing cromoglycates
JPS61158919A (ja)1984-12-281986-07-18Taisho Pharmaceut Co Ltd水虫治療剤
GB8820398D0 (en)*1988-08-271988-09-28Fisons PlcPharmaceutical formulation
IE62780B1 (en)*1988-09-101995-02-22Fisons PlcInhalation devices with a reduced risk of blockage
DE3839258A1 (de)*1988-11-211990-05-23Norbert SassVerfahren zur herstellung eines suspensions-aerosols
GB8828477D0 (en)1988-12-061989-01-05Riker Laboratories IncMedical aerosol formulations
US5225183A (en)1988-12-061993-07-06Riker Laboratories, Inc.Medicinal aerosol formulations
GB8921222D0 (en)*1989-09-201989-11-08Riker Laboratories IncMedicinal aerosol formulations
DE4003272A1 (de)1990-02-031991-08-08Boehringer Ingelheim KgNeue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
JP2854974B2 (ja)1990-06-291999-02-10フアイソンズ・ピーエルシー加圧エアロゾル組成物
HU205249B (en)*1990-11-091992-04-28Egyt Gyogyszervegyeszeti GyarProcess for producing suspensive aerosole composition
US5753208A (en)*1990-11-091998-05-19Egis GyogyszergyarAntiasthmatic aerosol preparation of sodium cromoglycate
EP0504112A3 (en)1991-03-141993-04-21Ciba-Geigy AgPharmaceutical aerosol formulations
CA2126244C (en)*1991-12-182000-09-26Robert K. SchultzSuspension aerosol formulations
ES2089357T3 (es)1991-12-311996-10-01Hoechst AgFormulacion medicinal en forma de aerosol.
SE523661C2 (sv)1992-02-052004-05-04American Pacific CorpGas-vätskeblandning avsedd för användning som brandsläckningsmedel
US5301664A (en)1992-03-061994-04-12Sievers Robert EMethods and apparatus for drug delivery using supercritical solutions
GB9214765D0 (en)1992-07-111992-08-26Smithkline Beecham PlcPressurised aerosol formulation
WO1994003056A1 (en)1992-07-311994-02-17Ian Alexander Edwin MaccormickAerosol insecticide composition
MY131733A (en)1994-12-222007-08-30Astra AbAerosol drug formulations
AP791A (en)*1995-04-141999-12-17Glaxo Wellcome IncMetered dose inhaler for albuterol.
DE19616573C2 (de)*1996-04-251999-03-04Pari GmbhVerwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
FR2764899B1 (fr)1997-06-192001-04-06Boehringer Ingelheim AlimentaiNouveau melange propulseur et les preparations alimentaires en aerosol le contenant

Also Published As

Publication numberPublication date
PT1102579E (pt)2003-07-31
CA2338680A1 (en)2000-02-17
ATE234604T1 (de)2003-04-15
EP1102579A1 (de)2001-05-30
CY2012033I2 (el)2015-08-05
NO2012019I2 (no)2014-06-02
NO20010531L (no)2001-01-31
LU92254I2 (fr)2013-09-17
DE59904648D1 (de)2003-04-24
CY2012033I1 (el)2015-08-05
NO2012019I1 (no)2012-12-27
JP4672143B2 (ja)2011-04-20
CA2338680C (en)2008-10-14
CN1315852A (zh)2001-10-03
US6475467B1 (en)2002-11-05
EP1102579B1 (de)2003-03-19
AU749697B2 (en)2002-07-04
WO2000007567A1 (de)2000-02-17
JP2002522374A (ja)2002-07-23
DK1102579T3 (da)2003-07-14
NO328096B1 (no)2009-12-07
NZ509489A (en)2002-10-25
NO20010531D0 (no)2001-01-31
BE2013C027I2 (es)2018-12-04
AU4893999A (en)2000-02-28
ZA200100569B (en)2001-09-26
FR13C0057I2 (fr)2020-04-03
FR13C0057I1 (es)2013-11-15
CN1150890C (zh)2004-05-26

Similar Documents

PublicationPublication DateTitle
ES2193726T3 (es)Formulaciones de aerosol medicinales.
ES2110212T3 (es)Composicion farmaceutica efervescente que contiene ibuprofeno y su procedimiento de preparacion.
AR028299A1 (es)Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
AR043863A1 (es)Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
CA2323680A1 (en)Orally disintegrable tablets
BRPI0406996A (pt)Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização
ES2185395T3 (es)Composiciones mucoadhesivas liquidas orales.
BRPI9811803B8 (pt)comprimido multiparticular aperfeiçoado de dissolução rápida
TR200100628T2 (tr)Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler.
CA2329005A1 (en)Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
BR0303348A (pt)Formulações de aerossol para administração pulmonar de medicamentos com o intuito de produzir efeito sistêmico
CO5170479A1 (es)Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado saturado y un mono de ester de acido acrilico. .
AU2003304237A8 (en)Gel-stabilized nanoparticulate active agent compositions
CR6656A (es)Forma de dosificacion de farmacos accionada por un hidrogel
BR0007445A (pt)Composições tendo fornecimento aperfeiçoado de ingredientes ativos
WO2002051424A8 (fr)Medicaments contre les defaillances articulaires
TW200630123A (en)Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
NO20030897D0 (no)Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
AR008355A1 (es)COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL.
AR030862A1 (es)Formulaciones medicinales en aerosol
ES2168241T1 (es)Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
SG149054A1 (en)Multiparticulate formulations for oral delivery
BR9913135A (pt)Formulação oral
BR0007428A (pt)Composições com estabilidade aprimorada
ES2099649T3 (es)Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida.

[8]ページ先頭

©2009-2025 Movatter.jp